Corient Private Wealth’s Anixa Biosciences ANIX Stock Holding History

Corient Private Wealth’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$105K	Buy	37,400 +17,400	+87%	+$48.4K	﹤0.01%	2909
2026 Q1	$51.6K	Sell	20,000 -54,800	-73%	-$162K	﹤0.01%	2757
2025 Q4	$233K	Buy	74,800 +37,400	+100%	+$153K	﹤0.01%	2564
2025 Q3	$123K	Hold	37,400	–	–	﹤0.01%	2421
2025 Q2	$123K	Hold	37,400	–	–	﹤0.01%	2305
2025 Q1	$107K	Hold	37,400	–	–	﹤0.01%	2161
2024 Q4	$86.8K	Hold	37,400	–	–	﹤0.01%	2239
2024 Q3	$118K	Hold	37,400	–	–	﹤0.01%	2308
2024 Q2	$82.7K	Hold	37,400	–	–	﹤0.01%	2230
2024 Q1	$117K	Hold	37,400	–	–	﹤0.01%	2171
2023 Q4	$145K	Buy	37,400 +17,400	+87%	+$58.7K	﹤0.01%	2117
2023 Q3	$65.4K	Hold	20,000	–	–	﹤0.01%	2065
2023 Q2	$64K	Hold	20,000	–	–	﹤0.01%	2005
2023 Q1	$86K	Hold	20,000	–	–	﹤0.01%	1902
2022 Q4	$85K	Buy	+20,000	New	+$96.2K	﹤0.01%	1586

Other funds holding ANIX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LNWTC

Laird Norton Wetherby Trust Company Seattle, Washington $5.21B AUM 31.48% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Corient Private Wealth's ANIX Position: Q2 2026 in Review

Corient Private Wealth increased its Anixa Biosciences (ANIX) stake by 87% in Q2 2026, buying an estimated $48.4K and bringing the position to 37,400 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #2909.

Corient Private Wealth first reported a position in ANIX in Q4 2022 and has held it in 15 quarters since. The position peaked at $233K in Q4 2025. 62 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.

Corient Private Wealth held 37,400 shares of Anixa Biosciences worth $105K as of Q2 2026.
Corient Private Wealth bought 17,400 Anixa Biosciences shares in Q2 2026, an estimated $48.4K.
Anixa Biosciences made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2909 holding.
Corient Private Wealth first reported a position in Anixa Biosciences in Q4 2022 and has held it in 15 quarters since.
Corient Private Wealth's Anixa Biosciences position peaked at $233K in Q4 2025.
62 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.